← Leaderboards
Manfred Windisch
Klogene Therapeutics, Inc.
$8,537,558
Attributed
$10,513,609
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3M · FY2016–22$5M$3.8M$2.5M$1.3M$0
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$10,513,609 · 4
By mechanism
R01$7,299,048 · 1
R44$2,989,673 · 2
R42$224,888 · 1
Top collaborators
- Carmela Abraham2 shared
- Menachem Abraham2 shared
- Vinai Gondi2 shared
- Victor Shifrin1 shared
- Simone Treiger Sredni1 shared
Most similar at Klogene Therapeutics, Inc.
Same institution · by research overlap
- Carmela Abraham$496,851
- Menachem Abraham$496,851
Others in their field
Top investigators on “Small Molecule”
- David Heimbrook · Leidos Biomedical Research, Inc.$251,072,489
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Peter C Adamson · National Childhood Cancer Foundation$143,645,434
- Mark S Klempner · Tufts Medical Center$128,021,180
- Stuart L Schreiber · Harvard University (Medical School)$79,067,419
- Edward A Dennis · University Of California, San Diego$73,030,813
Research focus
Small MoleculeBrainPharmaceutical PreparationsImpaired CognitionCognitiveSafetyNeuronsCognitive TestingClinical TrialsGrantDosePlacebosScheduleAffectCapsuleAlzheimer&AposFundingMeasurementHippocampus (Brain)Novel TherapeuticsOralBaseBioavailableDementia
Grant awards (10)
Mitigation of Radiation Therapy Induced Neuroinflammation and Cognitive Dysfunction$722,072
R44 · FY2022 · CA
Mitigation of Radiation Therapy Induced Neuroinflammation and Cognitive Dysfunction$777,049
R44 · FY2021 · CA · contact PI
A double-blinded, randomized, controlled phase 2a safety, proof-of-concept and exploratory end point trial of the drug LM11A-31 in patients with mild to moderate Alzheimer's disease.$2,559,183
R01 · FY2019 · AG · contact PI
A double-blinded, randomized, controlled phase 2a safety, proof-of-concept and exploratory end point trial of the drug LM11A-31 in patients with mild to moderate Alzheimer's disease.$245,000
R01 · FY2019 · AG · contact PI
Mitigation of Radiation Therapy Induced Neuroinflammation and Cognitive Dysfunction$224,888
R42 · FY2019 · CA · contact PI
A double-blinded, randomized, controlled phase 2a safety, proof-of-concept and exploratory end point trial of the drug LM11A-31 in patients with mild to moderate Alzheimer's disease.$1,495,447
R01 · FY2018 · AG · contact PI
A double-blinded, randomized, controlled phase 2a safety, proof-of-concept and exploratory end point trial of the drug LM11A-31 in patients with mild to moderate Alzheimer's disease.$1,499,544
R01 · FY2017 · AG · contact PI
A NOVEL NEUROPROTECTIVE THERAPY FOR ALZHEIMERâS DISEASE$468,418
R44 · FY2017 · AG
A double-blinded, randomized, controlled phase 2a safety, proof-of-concept and exploratory end point trial of the drug LM11A-31 in patients with mild to moderate Alzheimer's disease.$1,499,874
R01 · FY2016 · AG · contact PI
A NOVEL NEUROPROTECTIVE THERAPY FOR ALZHEIMERâS DISEASE$1,022,134
R44 · FY2016 · AG